Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc Logo
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 89.09 USD 0.99% Market Closed
Market Cap: 9.4B USD
Have any thoughts about
Intra-Cellular Therapies Inc?
Write Note

Intra-Cellular Therapies Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Intra-Cellular Therapies Inc
Revenue Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Revenue
$613.7m
CAGR 3-Years
106%
CAGR 5-Years
N/A
CAGR 10-Years
85%
Johnson & Johnson
NYSE:JNJ
Revenue
$87.7B
CAGR 3-Years
-1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$47.4B
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$60.1B
CAGR 3-Years
-4%
CAGR 5-Years
14%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Revenue
$63.2B
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
4%
Eli Lilly and Co
NYSE:LLY
Revenue
$40.9B
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
7%

Intra-Cellular Therapies Inc
Revenue Breakdown

Breakdown by Geography
Intra-Cellular Therapies Inc

Not Available

Breakdown by Segments
Intra-Cellular Therapies Inc

Total Revenue: 464.4m USD
100%
Product Sales, Net: 462.2m USD
99.5%
Grant Revenue: 2.2m USD
0.5%

See Also

What is Intra-Cellular Therapies Inc's Revenue?
Revenue
613.7m USD

Based on the financial report for Sep 30, 2024, Intra-Cellular Therapies Inc's Revenue amounts to 613.7m USD.

What is Intra-Cellular Therapies Inc's Revenue growth rate?
Revenue CAGR 10Y
85%

Over the last year, the Revenue growth was 46%. The average annual Revenue growth rates for Intra-Cellular Therapies Inc have been 106% over the past three years , and 85% over the past ten years .

Back to Top